-
MacroGenics NASDAQ:MGNX MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Location: 9704 Medical Center Dr, Maryland, 20850-3343, US | Website: www.macrogenics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
36.46M
Cash
200.4M
Avg Qtr Burn
-14.5M
Short % of Float
10.02%
Insider Ownership
2.65%
Institutional Own.
93.65%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer | Approved Quarterly sales | |
Retifanlimab (anti-PD-1 mAb) Details Solid tumor/s, Anal cancer, Non-small cell lung carcinoma, Lung cancer, Cancer | Phase 3 Data readout | |
Enoblituzumab (anti-B7-H3) Details Prostate cancer | Phase 2 Data readout | |
Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel Details Castration-resistant prostate cancer, Cancer, Solid tumor/s | Phase 2 Data readout | |
Vobramitamab duocarmazine (vobra duo) (MGC018) Details Castration-resistant prostate cancer, Cancer, Solid tumor/s | Phase 2 Data readout | |
MGC026 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
MGD024 Details Acute myeloid leukemia, Myelodysplastic syndrome | Phase 1 Data readout | |
Flotetuzumab (bispecific CD123 × CD3 DART molecule) Details Cancer, Multiple myeloma, Acute myeloid leukemia | Failed Discontinued | |
Margetuximab (Fc-engineered, anti-HER2 mAb) Details Gastric cancer, Cancer | Failed Discontinued | |
Vobramitamab duocarmazine (vobra duo) w/lorigerlimab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Melanoma, Castration-resistant prostate cancer | Failed Discontinued | |
Enoblituzumab (anti-B7-H3) Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued |